Powered by
LOS ANGELES—Officials at the St. Baldrick’s Foundation has named two Michigan hospitals among 17 grant winners of $819,000 in grants to advance research into children’s cancers. The Los Angeles-based foundation …
DETROIT—Officials at the Karmanos Cancer Institute in Detroit have announced the launch of a new clinical trials study information portal (SIP) at www.karmanos.org/opentrials. The SIP website, which is integrated with …
ANN ARBOR—HistoSonics Inc. announced that it had received an Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration (FDA) to begin a clinical trial of its new technology, …
CANTON TWP.—MMS Holdings Inc. said that its collaboration with Shanghai-based Green Valley Pharmaceutical Co. resulted in gaining U.S. Food & Drug Administration approval of an Investigational New Drug application for …
DETROIT—An oral therapy that has been studied in laboratory experiments and clinical trials at the Barbara Ann Karmanos Cancer Institute, in partnership with Karyopharm Therapeutics Inc., will soon enter clinical …
CANTON TWP.—MMS Holdings Inc., a contract research organization for the pharmaceutical industry, announced the hiring of Kelly Valliant as director of global transparency strategy and compliance. Vaillant will lead transparency …
CANTON TWP.—TrialAssure, a software company focused on developing clinical trial transparency tools, announced that it will offer academic institutions free access to TrialAssure Registry, its clinical trial disclosure reporting application. …
ANN ARBOR—Millendo Therapeutics Inc., a biopharmaceutical company primarily focused on developing novel treatments for endocrine diseases, announced today that it is discontinuing the development of livoletide as a potential treatment …
ALLENDALE—QST Consultations Ltd. has announced that it has changed its name to Abond CRO Inc., launching the new brand through a new website and participation at participation at the Summit …
FARMINGTON HILLS—Ocuphire Pharma Inc., a startup pharmaceutical company focused on the development and commercialization of therapies to treat patients with a variety of ophthalmic disorders, announced statistically significant and clinically …